EMA Application withdrawn: Datopotamab deruxtecan Daiichi Sankyo (datopotamab deruxtecan) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

EMA has withdrawn the marketing authorization application for datopotamab deruxtecan by Daiichi Sankyo Europe GmbH for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Datopotamab Deruxtecan (datopotamab deruxtecan)

Snippet

Status: Application withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Daiichi Sankyo Europe GmbH